baricitinib Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 5202 1187594-09-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • baricitinib
  • LY3009104
  • INCB028050
  • olumiant
Baricitinib is a selective and reversible inhibitor of Janus kinase (JAK)1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function. Within the intracellular signalling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which activate gene expression within the cell. Baricitinib modulates these signalling pathways by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of STATs.
  • Molecular weight: 371.42
  • Formula: C16H17N7O2S
  • CLOGP: 0.41
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 120.56
  • ALOGS: -3.02
  • ROTB: 4

Drug dosage:

DoseUnitRoute
4 mg O

Approvals:

DateAgencyCompanyOrphan
May 31, 2018 FDA ELI LILLY AND CO
July 3, 2017 PMDA Eli Lilly Japan KK
Feb. 13, 2017 EMA Eli Lilly Nederland B.V.

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapy cessation 106.96 39.58 24 331 8876 4629761
Rheumatoid arthritis 52.38 39.58 17 338 24982 4613655
Volvulus 48.19 39.58 8 347 595 4638042

Pharmacologic Action:

SourceCodeDescription
ATC L04AA37 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
FDA EPC N0000190858 Janus Kinase Inhibitor
FDA MoA N0000190857 Janus Kinase Inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148
Coronavirus infection off-label use 186747009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.49 acidic
pKa2 4.6 Basic
pKa3 1.9 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2MG OLUMIANT ELI LILLY AND CO N207924 May 31, 2018 RX TABLET ORAL 8420629 March 10, 2029 TREATMENT OF RHEUMATOID ARTHRITIS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
2MG OLUMIANT ELI LILLY AND CO N207924 May 31, 2018 RX TABLET ORAL May 31, 2023 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase JAK1 Kinase INHIBITOR IC50 8.23 SCIENTIFIC LITERATURE DRUG LABEL
Tyrosine-protein kinase JAK2 Kinase INHIBITOR IC50 8.24 SCIENTIFIC LITERATURE DRUG LABEL
Non-receptor tyrosine-protein kinase TYK2 Kinase INHIBITOR IC50 7.28 SCIENTIFIC LITERATURE
Tyrosine-protein kinase JAK3 Kinase IC50 6.10 CHEMBL

External reference:

IDSource
2047232 RXNORM
32650 MMSL
d08568 MMSL
763701005 SNOMEDCT_US
4037600 VANDF
017220 NDDF
726518002 SNOMEDCT_US
44205240 PUBCHEM_CID
D10308 KEGG_DRUG
ISP4442I3Y UNII
9570 INN_ID
3JW PDB_CHEM_ID
DB11817 DRUGBANK_ID
7792 IUPHAR_LIGAND_ID
CHEMBL2105759 ChEMBL_ID
C000596027 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Olumiant HUMAN PRESCRIPTION DRUG LABEL 1 0002-4182 TABLET, FILM COATED 2 mg ORAL NDA 19 sections
Olumiant HUMAN PRESCRIPTION DRUG LABEL 1 0002-4732 TABLET, FILM COATED 1 mg ORAL NDA 19 sections